EID Parry logo

EID Parry

EIDPARRY NSE

Key Fundamentals

MicrocapFertilizersChemicals
Market Cap
₹12,873 Cr
Volatility
Moderate
P/E Ratio
27.59
EBITDA
₹3,799 Cr
Return on Equity
9.25%
Debt to Equity
0.4
Book Value
₹495.35
EPS
₹49.62
52W High
₹1,118
52W Low
₹698.2

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 9.49% over last 3 years.
  • Dividend payout has been low at 2.63% of profits over last 3 years
  • Promoter holding has decreased over last 3 years: -3.24%

Growth Rate

Revenue Growth
21.63% higher than 3Y
Net Income Growth
-22.12% lower than 3Y
Cash Flow Change
-20.39% higher than 3Y
ROE
-32.53% lower than 3Y
ROCE
-21.13% higher than 3Y
EBITDA Margin (Avg.)
2.52% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 17d ago
AI opinion · based on fundamentals
Risk medium

EID Parry (India) Ltd trades at a market cap of ₹14,058 Cr with a PE of 11.6x and PB of 1.61x. The company has delivered 16% TTM sales growth but profits have declined 10% TTM, with 3-year ROE averaging just 9%. The stock has corrected 30% over the past year after delivering 19% CAGR over 3 years.

Bull Case 7
  • Attractive valuation with PE of 11.6x, below many peers in the chemicals/sugar space
  • Strong TTM revenue growth of 16% indicates improving top-line momentum
  • Long-term compounded profit growth of 35% over 10 years demonstrates earnings power over cycles
  • 5-year compounded sales CAGR of 16% shows sustained business expansion
  • Price-to-book of 1.61x is reasonable for a company with decade-long 12% ROE track record
  • Stock CAGR of 14% over 5 years and 12% over 10 years shows long-term wealth creation
  • 5-year compounded profit growth of 7% positive despite recent cyclical headwinds
Bear Case 8
  • Stock has declined 30% in the last 1 year, indicating significant near-term weakness
  • Compounded profit has declined 11% over 3 years, showing sustained earnings deterioration
  • Low 3-year ROE of only 9% suggests poor capital efficiency
  • Dividend payout of just 2.63% of profits over 3 years signals poor shareholder return policy
  • Promoter holding has decreased by 3.24% over last 3 years, raising governance concerns
  • Dividend yield of only 0.5% provides minimal income support to investors
  • TTM profit decline of 10% despite 16% sales growth indicates margin compression
  • Last year ROE dropped to 8% from 5-year average of 12%, showing declining return profile

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 12d ago
Headwinds 2
  • Consolidated PAT drops 42% YoY Aug 12

    Q1FY27 consolidated PAT fell to ₹142 crore from ₹246 crore YoY, hit by impairment charges and lower segment margins despite revenue rising 3.4% to ₹9,017 crore.

  • CPG turnover halves in Q1 Aug 19

    CPG segment turnover dropped 50% to ₹94 crore in Q1FY27, and the company had to infuse ₹665 crore to settle PSRIPL liabilities.

Positives 2
  • Sugar revenue up 18% YoY Aug 19

    Q1FY27 sugar revenue rose 18% YoY to ₹410 crore on higher volumes, indicating strong performance in the core sugar segment.

  • Jaggery capacity doubling via Karnataka Aug 14

    EID Parry plans to double jaggery capacity with a new Karnataka plant targeting ₹100 crore turnover. Nutraceuticals is aiming for record revenue with 12-15% EBITDA margins.

Neutral 2
  • Independent Director retires from board Aug 4

    Dr. Rea Godbole retired from EID Parry's board effective August 4, 2026, after completing two consecutive terms as Independent Director.

  • CPG breakeven in 4-5 quarters Aug 14

    Management guided that the CPG segment is targeting breakeven within four to five quarters, signaling a medium-term turnaround timeline.

TL;DR: EID Parry's core sugar business is performing well with 18% revenue growth, and capacity expansion into jaggery and nutraceuticals signals diversification intent. However, a 42% PAT decline driven by impairment charges and a halving of CPG revenue are significant near-term concerns. The ₹665 crore PSRIPL liability settlement adds to balance sheet pressure. The trend is mixed — sugar fundamentals are solid but profitability recovery hinges on CPG turnaround and absence of further one-off charges.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
7,026
9,059
7,770
5,557
6,747
9,330
8,720
6,811
8,720
11,624
10,312
7,882
9,018
Expenses
6,363
8,006
7,358
5,098
6,279
8,372
8,027
6,298
7,914
10,427
9,477
7,271
8,267
Operating Profit
664
1,053
412
459
468
959
694
513
805
1,198
835
611
751
OPM %
9%
12%
5%
8%
7%
10%
8%
8%
9%
10%
8%
8%
8%
Other Income
-11
151
41
123
60
69
117
459
90
151
60
-430
30
Interest
82
74
53
86
84
94
99
96
104
129
103
119
115
Depreciation
94
101
112
113
117
123
130
142
176
158
204
226
243
PBT
477
1,029
288
382
327
811
582
735
615
1,062
588
-162
423
Tax %
32%
24%
25%
23%
31%
27%
29%
27%
25%
28%
26%
77%
26%
Net Profit
325
782
217
294
226
592
416
539
464
766
437
-287
312
EPS in Rs
6.13
25.48
6.66
12.41
5.14
17.21
10.97
16.12
13.85
23.86
13.05
-18.74
7.96
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
13,952
15,358
14,391
15,373
16,556
17,129
18,556
23,521
35,244
29,413
31,609
38,534
38,836
Expenses
12,938
14,517
12,965
14,068
15,105
15,242
16,467
21,146
32,088
26,825
28,975
35,085
35,442
Operating Profit
1,014
841
1,426
1,305
1,450
1,887
2,089
2,375
3,156
2,588
2,633
3,450
3,395
OPM %
7%
5%
10%
8%
9%
11%
11%
10%
9%
9%
8%
9%
9%
Other Income
105
179
159
150
83
129
17
240
83
304
706
-129
-189
Interest
420
451
417
336
425
430
236
152
298
295
372
454
465
Depreciation
244
250
248
251
272
319
332
334
376
421
512
763
830
PBT
455
319
920
868
837
1,266
1,539
2,129
2,564
2,175
2,455
2,103
1,911
Tax %
39%
45%
23%
40%
48%
30%
35%
26%
29%
26%
28%
34%
—
Net Profit
276
175
708
517
438
889
1,000
1,574
1,828
1,618
1,773
1,380
1,227
EPS in Rs
6.64
1.96
29.61
14.45
8.67
26.43
25.26
51.12
53.37
50.68
49.41
32.02
26.13
Div. Payout %
89%
0%
14%
21%
35%
0%
0%
22%
18%
8%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
18
18
18
18
18
18
18
18
18
18
18
18
Reserves
2,209
2,370
2,733
2,952
3,110
3,502
4,565
5,308
6,067
7,040
7,918
8,748
Borrowings
4,823
5,144
3,923
4,470
5,125
4,347
1,229
1,259
1,618
1,740
2,704
3,528
Other Liabilities
5,849
6,600
6,691
7,088
7,649
7,069
7,444
9,358
11,076
12,688
13,731
16,917
Total Liabilities
12,899
14,131
13,364
14,528
15,901
14,936
13,257
15,943
18,778
21,487
24,371
29,212
Fixed Assets
3,476
3,343
3,297
3,197
3,077
3,858
3,583
3,763
3,889
4,896
6,148
8,240
CWIP
75
77
39
54
203
85
206
160
486
520
422
357
Investments
369
688
569
430
418
413
453
563
609
1,275
1,453
2,477
Other Assets
8,979
10,022
9,459
10,847
12,203
10,579
9,014
11,456
13,794
14,796
16,348
18,138
Total Assets
12,899
14,131
13,364
14,528
15,901
14,936
13,257
15,943
18,778
21,487
24,371
29,212
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
222
437
1,969
259
-52
1,986
4,771
2,278
359
1,974
1,936
1,542
Investing
-307
-192
-148
13
-357
-282
-548
-1,732
487
-1,740
-2,783
-173
Financing
-142
-221
-1,842
42
34
-1,769
-3,598
-499
-184
-497
74
-551
Net Cash Flow
-227
23
-21
314
-375
-65
625
47
661
-263
-772
818
Free Cash Flow
35
233
1,839
82
-396
1,628
4,455
1,845
-370
1,051
1,323
5
CFO/OP
36
73
160
48
24
126
252
117
33
101
102
67
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
45
49
47
43
46
45
17
9
8
23
20
22
Inventory Days
138
124
127
134
175
131
112
111
81
112
101
107
Days Payable
141
145
170
174
172
141
124
114
84
121
113
116
Cash Conversion Cycle
42
27
4
3
49
35
6
6
5
14
8
13
Working Capital Days
-1
2
15
4
17
36
45
29
27
27
14
21
ROCE %
11%
9%
16%
16%
14%
18%
21%
26%
27%
20%
17%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view EID Parry insights

66 extracted metrics + investor summaries across FY09–FY26.

Log in — free

Shareholding Pattern

Public23.97%Promot.41.28%Others6.88%FIIs11.21%DIIs16.67%As ofJun 2026

Documents

Frequently Asked Questions about EID Parry

What does EID Parry (India) Ltd do?
EID Parry is engaged in Sugar, Nutraceuticals and ethanol production. It also has a significant presence in the Farm Inputs business including Bio pesticides through its subsidiary, Coromandel International Limited. [1]
Where is EID Parry (India) Ltd (EIDPARRY) listed?
EID Parry (India) Ltd trades as EIDPARRY on the NSE and under code 500125 on the BSE.
Which sector does EID Parry (India) Ltd belong to?
EID Parry (India) Ltd is classified under the Chemicals sector, in the Fertilizers industry.
What is the market capitalisation of EID Parry (India) Ltd?
EID Parry (India) Ltd has a market capitalisation of ₹12,873 Cr, which places it in the Mid Cap band.
What is the PE ratio of EID Parry (India) Ltd?
EID Parry (India) Ltd trades at a PE ratio of 27.59, on earnings per share of ₹49.62, against a book value of ₹495.35 per share.
What is the 52-week high and low of EID Parry (India) Ltd?
Over the last 52 weeks EID Parry (India) Ltd has traded between ₹698.2 and ₹1,118.
Does EID Parry (India) Ltd pay dividends?
EID Parry (India) Ltd has a dividend yield of 0.54%.
What is the Return on Equity (ROE) of EID Parry (India) Ltd?
EID Parry (India) Ltd reported a return on equity of 9.25%. Its debt-to-equity ratio is 0.40.

Company Information

EID Parry is engaged in Sugar, Nutraceuticals and ethanol production. It also has a significant presence in the Farm Inputs business including Bio pesticides through its subsidiary, Coromandel International Limited. [1]

Website eidparry.com
CEO Mr. Muthiah Murugappan
Employees 2,384
Listed 1995-05-10
Face Value ₹ 1
Issued Size 17,78,72,717

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/EIDPARRY.md for EID Parry (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Chemicals → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List